Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Burgeoning INDs

WASHINGTON - The FDA's Center for Biologics Evaluation and Research has received as many IND and IDE applications in the first eight months of 1997 as it did during 1996, and it expects the total for the year to set a record, according to CBER Director Kathryn Zoon.Zoon told a meeting of the Food

Read the full 548 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE